DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06278285

Maigrir_OT

RecruitingPhase NA

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

1

Enrollment

40

estimated

Study population

Bariatric Surgery, Obesity / overweight

Key I/E criterion

•BMI ≥35

Primary endpoint

•Oxytocin

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06278285
Org study ID21-AOIP-01

Timeline

Milestones

Study first posted2024-02-26actual
Study start2024-03-06actual
Last update posted2026-03-27actual
Primary completion2026-09-06estimated
Study completion2027-03-06estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Bariatric SurgeryObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patient over 18 years of age.
•Patient able to read and understand the information/consent leaflet.
•Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
•Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
•Membership of a social security scheme
•Patient's signed informed consent
•For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
•For non-GLP-1 analogue group: never taken GLP-1 analogues.

Exclusion criteria

•Pregnant or breast-feeding women.
•Vulnerable patients (under guardianship)
•Patients deprived of liberty

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Rate of oxytocin

Time frame:one time (before surgery)

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Fibrosis rate

Time frame:At surgery

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.